Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11947825 | 0.86 | CYP3A4 (0.53) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL13168323 | 0.83 | HSD17B10 (0.53) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL19440754 | 0.79 | LMNA (0.47) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL22016879 | 0.79 | — | — | |
| SCHEMBL13168230 | 0.78 | CYP3A4 (0.49) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL11956175 | 0.77 | CYP2D6 (0.53) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL14996534 | 0.76 | CYP3A4 (0.59) | CYP2D6CYP3A4TSHRMEN1KMT2A | |
| SCHEMBL24276408 | 0.76 | CYP2D6 (0.33) | CYP2D6CYP3A4TSHRHSD17B10CYP1A2 | |
| SCHEMBL19966681 | 0.74 | HRH3 (0.43) | MEN1KMT2AHSD17B10ALDH1A1USP2 | |
| SCHEMBL22752283 | 0.71 | TSHR (0.41) | CYP2D6CYP3A4TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | BDKRB1, BDKRB2, BRD1 | CYP2D6 1223/4885CYP3A4 253/4885TSHR 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.